Table 2.

Differential Benefit for Probands and Mutation-Carrying Relatives, by Sex, With Selected Strategies and Varying Rates of Germline Testing Acceptance and Adherence With Preventive Interventions

Scenario and Patient	MMRpro/Germline vs. Referent Strategy*			IHC With BRAF Testing vs. Referent Strategy*
	Discounted Incremental Life-Years per Person	Undiscounted Incremental Life-Years per Person	Discounted Cost per Life-Year Gained, $	Discounted Incremental Life-Years per Person	Undiscounted Incremental Life-Years per Person	Discounted Cost per Life-Year Gained, $
Base case
Female proband	0.174	0.365	83 300	0.191	0.401	106 600
Male proband	0.084	0.171	131 900	0.092	0.187	180 400
Female mutation-carrying relative	0.442	1.37	16 800	0.485	1.51	16 800
Male mutation-carrying relative	0.461	1.31	7400	0.506	1.44	7400
Universal acceptance of germline testing and perfect screening adherence
Female proband	0.226	0.473	76 300	0.248	0.519	92 800
Male proband	0.108	0.219	117 900	0.118	0.240	152 500
Female mutation-carrying relative	0.768	2.39	16 900	0.843	2.62	16 900
Male mutation-carrying relative	0.801	2.28	7600	0.880	2.50	7600
Universal acceptance of germline testing, perfect screening adherence, and prophylactic TAH-BSO at age 40 y in all probands and relatives with the Lynch syndrome
Female proband	0.576	1.20	37 100	0.632	1.32	43 600
Female mutation-carrying relative	1.06	3.46	13 300	1.16	3.79	13 300

IHC = immunohistochemistry; TAH-BSO = total abdominal hysterectomy and bilateral salpingo-oophorectomy.

^*The referent strategy reflects no active effort to diagnose the Lynch syndrome.